MTOR and colorectal carcinoma: Due to the complexity of drug resistance and the mTOR pathway, combination therapies targeting multiple nodes in the pathway or combining mTOR inhibitors with other agents are being investigated as potential strategies to improve treatment outcomes in CRC patients with mTOR pathway mutations [371].